This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Diabetes, is properly cited. The complete bibliographic information, a link to the original publication on https://diabetes.jmir.org/, as well as this copyright and license information must be included.
With increasing type 2 diabetes prevalence, there is a need for effective programs that support diabetes management and improve type 2 diabetes outcomes. Mobile health (mHealth) interventions have shown promising results. With advances in wearable sensors and improved integration, mHealth programs could become more accessible and personalized.
The study aimed to evaluate the feasibility, acceptability, and effectiveness of a personalized mHealth-anchored intervention program in improving glycemic control and enhancing care experience in diabetes management. The program was coincidentally implemented during the national-level lockdown for COVID-19 in Singapore, allowing for a timely study of the use of mHealth for chronic disease management.
Patients with type 2 diabetes or prediabetes were enrolled from the Singapore Armed Forces and offered a 3-month intervention program in addition to the usual care they received. The program was standardized to include (1) in-person initial consultation with a clinical dietitian; (2) in-person review with a diabetes specialist doctor; (3) 1 continuous glucose monitoring device; (4) access to the mobile app for dietary intake and physical activity tracking, and communication via messaging with the dietitian and doctor; and (5) context-sensitive digital health coaching over the mobile app. Medical support was rendered to the patients on an as-needed basis when they required advice on adjustment of medications. Measurements of weight, height, and glycated hemoglobin A1c (HbA1c) were conducted at 2 in-person visits at the start and end of the program. At the end of the program, patients were asked to complete a short acceptability feedback survey to understand the motivation for joining the program, their satisfaction, and suggestions for improvement.
Over a 4-week recruitment period, 130 individuals were screened, the enrollment target of 30 patients was met, and 21 patients completed the program and were included in the final analyses; 9 patients were lost to follow-up (full data were not available for the final analyses). There were no differences in the baseline characteristics between patients who were included and excluded from the final analyses (age category:
The personalized mHealth program was feasible, acceptable, and produced significant reductions in HbA1c (
Close to half a billion people in the world live with type 2 diabetes, and this prevalence is expected to increase by 25% by 2030 [
Lifestyle and behavior modification interventions for the prevention and management of type 2 diabetes have been shown to be effective in reducing risk of disease progression [
Simultaneously, many of these traditional lifestyle and behavior modification intervention programs have been found to have low participation rates [
The use of mHealth for lifestyle and behavior modification interventions capitalizes on easily rolled out technologies to make communication and self-management education components easily accessible and independent of location. Over the years, mHealth interventions have progressed from using phone calls, text messages, and internet websites to, more recently, smartphone apps. The use of mHealth interventions for chronic disease care and management has been well-received with high acceptability and engagement [
The use of wearable sensors in mHealth interventions provides real-time tracking and monitoring in patients with type 2 diabetes. Self-monitoring of blood glucose level, either by finger-stick or continuous glucose monitoring (CGM) technology, has been shown to be useful in helping patients improve their diabetes control [
Given the increasing burden and cost of uncontrolled type 2 diabetes and related complications, there is a great urgency for scalable and effective solutions that reduce such a burden and cost [
The program was conducted in Singapore, a city-state in tropical Southeast Asia with a population of 5.64 million people [
The patients were recruited from active full-time service personnel and conscripts. Invitation to participate in the program was conducted by the Singapore Armed Forces’ Headquarters Medical Corps through a series of intranet publicity advertisements posted over 4 weeks in February 2020. Interested patients were screened by the Headquarters Medical Corps and were enrolled into the program if they were interested and met the eligibility criteria (of having type 2 diabetes or prediabetes). The patients were deemed to have (1) type 2 diabetes, if they had glycated hemoglobin (HbA1c) ≥6.5% in the past 1 year or if they were on medication for type 2 diabetes, or (2) prediabetes, if they had an HbA1c level in the range 5.7% to 6.4% in the past year, and they were not taking any medications for type 2 diabetes. The enrollment target was set at 30 individuals, which was deemed to be sufficient to assess the feasibility and acceptability of such an intervention in a pilot program [
The Singapore Armed Forces’ Headquarters Medical Corps worked with NOVI Health, a health care technology start-up based in Singapore, to provide their proprietary mHealth program to the enrolled population.
All eligible patients were offered the 3-month intervention program in addition to the usual care that they received for their type 2 diabetes or prediabetes (
Intervention program timeline and protocol. *Recruitment with a series of publicity advertisements on the Singapore Armed Forces’ intranet. ^Glycated hemoglobin level (HbA1c) was measured if there was no valid reading within the prior 3 months.
Screenshots of mobile app dashboard with diet and physical activity goals, real-time continuous glucose monitoring data, dietary intake and physical activity logs, and personalized recommendations delivered through the messaging function in the mobile app.
In the first in-person visit to the clinic (Visit 1), the patients had a consultation with the dietitian to set their health goals and discuss behavioral lifestyle changes that could be made. The patients also had a consultation with the diabetes specialist doctor, which allowed for the review of comorbidities and medication regime. The patients were also provided with 1 CGM device and were guided on how to use the device for glucose monitoring and how to provide the care team with access to their real-time CGM data.
In the subsequent 3 months after Visit 1, the patients were free-living and used the mobile app to log their dietary intake and physical activity. The dietitian and doctor were able to view the CGM, dietary intake, and physical activity data together with available information on the patients’ health status (information on HbA1c, comorbidities, and medication regime). This allowed them to deliver timely personalized recommendations through the messaging function of the mobile app. The health coaching via the mobile app was led by the clinical dietitian, with input from the fitness coaches provided when needed, and with medical oversight from the reviewing diabetes specialist doctor. Medical support via the mobile app was also provided to the patients on an as-needed basis (if they experienced hypoglycemia requiring medication adjustments or if they required advice on the adjustment of medications, etc). After 3 months, the patients returned to the clinic for their second in-person visit (Visit 2) to meet with the diabetes specialist doctor and dietitian for final review.
Patient recruitment for the program started in February 2020 and the program ran from March 2020 to June 2020. The recruitment period and the first month of the intervention program corresponded with a worsening COVID-19 situation in Singapore through the months of February and March 2020. This culminated in a national-level lockdown, which started on April 7, 2020 and ended on June 1, 2020, coinciding with the second and third months of the intervention program. The 2 in-person visits to the clinic (Visits 1 and 2) happened to have been scheduled in the periods before and after the lockdown in Singapore and were, therefore, not impacted.
Measurements of weight, height, and HbA1c were conducted at Visits 1 and 2. Weight and height were measured by a trained nurse, using a Surgico Healthweigh machine. At the end of the program at Visit 2, the patients were asked to complete a short acceptability feedback survey to understand the motivation for joining the program, their satisfaction, and suggestions for improvement. The question on motivation, “What was your primary motivation for signing up for this program?” had 4 options: “1. Wanted to get my diabetes under control, 2. Wanted to get dietary advice for my diabetes, 3. Wanted to lose weight, 4. Was asked to participate by HQMC.” There were 2 satisfaction questions rated on a 10-point Likert scale, “How satisfied were you with the program?” and “How likely are you to recommend this program to your colleague?” A fourth question “Do you think that other servicemen would benefit from this program?” was a Yes-No question asking the patients on whether the program would be beneficial to others.
Patients were considered to have completed the study and included in the final outcomes analyses if they had completed the full 14 weeks of the intervention program, with weight, height, and HbA1c measurements at baseline (Visit 1) and at completion of the program (Visit 2). Means were calculated for continuous baseline characteristic variables. Due to nonnormality of data, the Wilcoxon signed rank test was used to compare means between those who completed the study and those that were lost to follow-up and excluded. Proportions were calculated for baseline characteristics that were categorical variables. The Fisher exact test was used if counts were less than 5 to compare distributions of those who completed the study and those who were lost to follow-up and excluded.
The final analyses of main outcomes of interest for acceptability and effectiveness were limited to only the those who completed the study. For the outcomes of HbA1c, weight, and BMI, the patients were further split for subgroup analyses: (1) by baseline HbA1c ≤7% or >7%, and (2) by baseline BMI<27.5 kg/m2 (normal and overweight) or ≥27.5 kg/m2 (obese). The HbA1c cut-off was selected based on the HbA1c threshold set by major clinical guidelines for what is considered good diabetes control [
This study was conducted as part of a program evaluation. The data collected were presented at the Singapore Armed Forces’ Joint Medical Committee for Research and approved for exemption from full review at the Institutional Review Board.
Over the 4-weeks recruitment period in February 2020, there were 130 individuals screened, of whom 30 met eligibility criteria and were interested in participating in the program. Of the 30 enrolled patients, 7 were lost to follow-up, and 2 had completed the program but did not have complete measurements from Visit 2. As such, 21 patients were included in the final outcome analyses. There were no significant differences in any of the baseline characteristics (age category:
Baseline characteristics of all enrolled patients, patients lost to follow-up, and patients who completed the program and were included in the final analyses.
Characteristics | All recruited (n=30) | Lost to follow-up (n=9) | Completed (n=21) | ||
Age (years), mean (range) | 49.1 (21-64) | 43.7 (21-61) | 51.4 (32-64) | .054 | |
|
|
|
|
.23 | |
|
<50 years | 17 (57) | 7 (78) | 10 (48) |
|
|
≥50 years | 13 (43) | 2 (22) | 11 (52) |
|
|
|
|
|
.21 | |
|
Female | 9 (30) | 1 (11) | 8 (38) |
|
|
Male | 21 (70) | 8 (89) | 13 (62) |
|
|
|
|
|
>.99 | |
|
Chinese | 24 (80) | 8 (89) | 16 (76) |
|
|
Malay | 1 (3) | 0 (0) | 1 (5) |
|
|
Indian/Pakistani | 5 (17) | 1 (11) | 4 (19.0) |
|
|
|
|
|
.52 | |
|
Prediabetes | 2 (7) | 1 (11) | 1 (5) |
|
|
Type 2 diabetes | 28 (93) | 8 (89) | 20 (95) |
|
|
|
|
|
.65 | |
|
Adjusted | 8 (27) | 3 (33) | 5 (24) |
|
|
Not adjusted | 22 (73) | 6 (67) | 16 (76) |
|
Baseline HbA1ca (%), mean | 7.7 | 7.9 | 7.6 | >.99 | |
|
|
|
|
.69 | |
|
≤7% | 11 (37) | 4 (44) | 7 (33) |
|
|
>7% | 19 (63) | 5 (56) | 14 (67) |
|
Baseline BMIb (kg/m2), mean | 27.9 | 28.2 | 27.8 | .96 | |
|
|
|
|
>.99 | |
|
<27.5 kg/m2 | 15 (50) | 4 (44) | 11 (52) |
|
|
≥27.5 kg/m2 | 15 (50) | 5 (56) | 10 (48) |
|
Baseline weight (kg), mean | 77.7 | 79.7 | 76.8 | .82 |
aHbA1c: glycated hemoglobin.
bBMI: body mass index.
For the multiple-choice question on motivation, 48% of patients (10/21) selected “Wanted to get my diabetes under control,” 19% of patients (4/21) selected “Wanted to get dietary advice for my diabetes,” 3 (14% of patients (3/21) patients selected “Wanted to lose weight,” and 19% of patients (4/21) selected “Was asked to participate by HQMC.” The patients rated a mean of 9.0 out of 10 on the Likert scale for both satisfaction questions. For the Yes-No question on the benefit of the program, all patients selected “Yes.”
For all 21 who completed the study, mean HbA1c decreased from 7.6% to 7.0% (
Comparison of HbA1c, weight, and BMI at Visit 1 and Visit 2 for all patients who completed the study.
Outcome | Visit 1, mean (SD) | Visit 2, mean (SD) | |
HbA1ca (%) | 7.6 (1.1) | 7.0 (0.8) | .004 |
Weight (kg) | 76.8 (15.6) | 73.9 (13.8) | <.001 |
BMIb (kg/m2) | 27.8 (5.4) | 26.7 (4.8) | <.001 |
aHbA1c: glycated hemoglobin.
bBMI: body mass index.
For patients who had baseline HbA1c ≤7%, there was no statistically significant change in HbA1c upon completion of the 3-month intervention program (
Comparison of Visit 1 and Visit 2 characteristics for patients who had baseline HbA1c ≤7% or >7%.
Outcome | Baseline HbA1c ≤7% (n=7) | Baseline HbA1c >7% (n=14) | |||||
|
Visit 1, mean (SD) | Visit 2, mean (SD) | Visit 1, mean (SD) | Visit 2, mean (SD) | |||
HbA1ca (%) | 6.7 (0.3) | 6.6 (0.6) | .67b | 8.1 (1.0) | 7.2 (0.8) | .005 | |
Weight (kg) | 75.0 (13.5) | 73.0 (12.2) | .02 | 77.8 (16.9) | 74.3 (14.9) | .006 | |
BMIc (kg/m2) | 26.8 (5.1) | 26.1 (4.8) | .02 | 28.3 (5.7) | 27.1 (4.9) | .006 |
aHbA1c: glycated hemoglobin.
bType II beta error >.2.
cBMI: body mass index.
There were no statistically significant changes in HbA1c, weight, or BMI for patients who were in the normal and overweight BMI category, after the intervention in Visit 2, but beta errors were found to be >.2 (
Comparison of Visit 1 and Visit 2 characteristics for patients who had baseline BMI <27.5 kg/m2 (normal and overweight) or ≥27.5 kg/m2 (obese).
Outcome | Normal and overweight (n=11) | Obese (n=10) | |||||
|
Visit 1, mean (SD) | Visit 2, mean (SD) | Visit 1, mean (SD) | Visit 2, mean (SD) | |||
HbA1ca (%) | 7.7 (1.3) | 7.3 (0.9) | .14b | 7.6 (0.9) | 6.8 (0.6) | .006 | |
Weight (kg) | 65.5 (8.7) | 64.6 (8.1) | .07b | 89.3 (11.1) | 84.1 (11.2) | .002 | |
BMIc (kg/m2) | 23.5 (2.1) | 23.2 (2.03) | .07b | 32.5 (3.6) | 30.6 (3.7) | .002 |
aHbA1c: glycated hemoglobin.
bType II beta error >.2.
cBMI: body mass index.
During the study, the patients had no hospitalization episodes for any diabetes-related complications. There were no severe hypoglycemia (glucose level <3 mmol/L) events observed or reported.
This study evaluated a real-world personalized mHealth-anchored intervention program for feasibility, acceptability, and effectiveness for diabetes management. The program garnered a lot of interest and the enrollment target was met fairly quickly (in less than a month). The program was implemented as planned in spite of the disruptions from COVID-19. The program also received high patient ratings of satisfaction and perceived benefit from participation in the program. The patients achieved a significant reduction in HbA1c in 3 months, ending the program with an average HbA1c of 7%. Reduction of HbA1c levels to ≤7% is consistent with the glycemic target set by most clinical guidelines [
The improvements observed were achieved in patients who had known type 2 diabetes and prediabetes and who were receiving usual care and on existing medications. This suggests that there could be a role for a personalized mHealth program for patients with diabetes, even those receiving usual medical care for their diabetes. Such a program could improve control of diabetes and further reduce the risk of microvascular and macrovascular complications. In the subgroups of patients with glycemic and BMI measures above the ideal range, the impact of the personalized mHealth program was even greater. These results were not unexpected as the patients with starting HbA1c and weight values that were further from target were likely to have more room for improvement. The mHealth program could benefit most individuals with diabetes; targeting the program at individuals with higher HbA1c or higher BMI would yield greater improvements in both HbA1c and BMI.
Traditionally, diabetes management programs that supplement usual care for individuals with diabetes have focused on enhancing support and education, improving nutrition, and increasing physical activity with a structured curriculum-based approach [
The personalized mHealth program in this study combined health coach-led personalized lifestyle intervention with medical support by a specialist doctor, the use of CGM, and integrated delivery through a mobile app. The medical support allowed for medication adjustments where beneficial, for example, optimizing the timing of administration of the medication to more effectively suit the lifestyle patterns of the patient. However, it is important to note that, in this study, there were no major adjustments of medications, such as initiating patients on insulin, that could have confounded the improvements observed. This is in contrast to another feasibility study with the same mHealth components, in which it was not possible to determine if improvements were due to intensification of medical therapy or from the other components of the intervention program [
The mobile app and CGM allowed the real-time tracking of diet, physical activity, and glucose, for interventions that were highly personalized, context sensitive, and delivered in a timely manner. Visualization of their own data, coupled with remote monitoring and actionable insights from trusted experts through the mobile app to make sense of that data, could enable the patients to appreciate the impact of their behaviors on their own health parameters. This could have further empowered and reinforced the user to implement behaviors that improve their health on a continuous, real-time basis in between clinic visits, with a low risk of adverse events such as hypoglycemia. The integrated solution incorporating medical support, CGM, and lifestyle care delivery through a mobile app likely accounted for the intervention in this study achieving results comparable to those reported in other diabetes lifestyle intervention programs, in a far shorter period of 3 months.
Based on the responses from the survey at the end of the program, patients found this personalized mHealth program to be beneficial in improving their diabetes control. Patients also reported that they were satisfied with the personalized mHealth program. These results suggested that patients found value in the mHealth program and were also receptive to the program. As there was no glycemic threshold effect, participation in a personalized mHealth program could be recommended to most individuals with diabetes or prediabetes, with the understanding that greater clinical improvement is seen with poorer starting glycemic control.
This program was conducted against the backdrop of a worsening COVID-19 pandemic, which saw Singapore undergo a national-level lockdown, termed
With the closure of sports facilities, many of the patients who performed their physical activity in these locations were unable to continue doing so. Closure of workplaces and recreational facilities, as well as banning of social gatherings, meant that patients left their homes less and commuted less, resulting in lower physical activity levels [
During the circuit breaker period, the patients also had greater difficulty accessing health care. Many of the patients had their regular reviews with their primary care physicians postponed. Some of the patients in critical operational roles were confined to military camps, with some reporting difficulties getting refills of certain medications from their external health care providers, and in some instances, difficulties in communicating via the mobile app due to certain camp security restrictions. These health care access issues would have negatively impacted the patients’ diabetes care and control during this period.
The patients in this study experienced clinically significant improvements in their glycemic control (
This study evaluated a real-world context-sensitive mHealth-anchored intervention program with free-living patients. The program also coincidentally began during the start of the COVID-19 pandemic, with the bulk of the encounters occurring during the national-level lockdown in Singapore. This allowed for a timely study of the use of mHealth for chronic disease management just as the world needed to move toward embracing more digital solutions to limit in-person interactions.
A limitation of this study was that the program was conducted only with military personnel, which could have been expanded to include other professions so that the results could be more generalizable. However, the focus on military personnel could inform specific occupational policy changes to improve chronic disease prevention and management for active military personnel [
Another limitation was that the study consisted of a single intervention arm with no control group. Without a control group, there is a possibility that patients not undergoing the same program might still experience the same improvements with usual care during the same time period. However, this study demonstrated the feasibility of the program and also provided pilot data that can pave the way for future studies. Further explorations could be done on the improvements of the personalized mHealth program intervention and its various components.
Close to one-third of the patients had dropped out of the program. However, this was not higher than expected for a 3-month program, and we did not observe any systemic differences between the patients who completed the program compared to those who dropped out analyses (age category:
The patients were also only followed-up for 3 months until the end of the program; therefore, long-term effects of the program are unknown. This is a limitation commonly found in the review of other mHealth interventions [
The personalized mHealth-anchored intervention program demonstrated feasibility and acceptability and was able to produce significant reductions in HbA1c (
body mass index
continuous glucose monitoring
glycated hemoglobin A1c
mobile health
The intervention program was a contracted health service paid for by the Singapore Armed Forces. Funding for the publication of this manuscript was provided by the Singapore Ministry of Health’s National Medical Research Council Centre Grant Programme (grant number NMRC/CG/C026/2017_NUHS) for SPHERiC (the Singapore Population Health Improvement Centre). We would like to acknowledge senior dietitian Ruth Ho and staff nurse Liu Qing for their contributions to the delivery of the intervention program, as well as Nabilah Rahman for providing statistical advice.
KTXQ, SAT, TCH, and CT were responsible for the design of the intervention program. TCH and JT assisted with recruitment of patients for the program and operational aspects of the implementation of the program. IYHA was responsible for data analysis. IYHA and KTXQ wrote the first draft of the manuscript. All authors provided input, edited, and approved the final draft of this paper.
KTXQ, JT, and SAT are cofounders and shareholders of NOVI Health. IYHA, CT, TCH, and JWMK declare no conflicts of interest.